01—Abstract
Summary
Summary of the 8-K filed May 14, 2026. Cited figures are marked; the original filing is the authoritative source.
Biogen (BIIB) has completed its acquisition of Apellis Pharmaceuticals (APLS), a deal announced March 31, 2026.
The tender offer expired May 13, 2026, with about 105.7 million shares tendered (roughly 82.4% of outstanding shares), satisfying the minimum condition. Purchaser accepted the shares for payment on May 14, 2026, and Apellis was merged into a Biogen subsidiary under DGCL Section 251(h) without a stockholder vote. Shareholders receive $41.00a in cash plus one non-transferable contingent value right (CVR) per share.
The total cash outlay is about $5.3 billionb, excluding fees and CVR payments, and Biogen estimates up to about $582 million more if all CVR milestones are met. Management says the deal adds EMPAVELI and SYFOVRE, which generated $689 million in combined 2025 net product revenue, and expects it to be accretive to non-GAAP EPS in 2027. Updated guidance is due with Q2 earnings in July.
Financing is a $2 billionc unsecured term loan from U.S. Bank, signed May 12, 2026 and fully drawn May 13. It has a $1 billion 364-day Tranche A (SOFR plus 0.75%, due May 2027) and a $1 billion two-year Tranche B (SOFR plus 0.75%–1.00%, due May 2028). Biogen must keep consolidated leverage at or below 3.75x, temporarily flexible to 4.25x after material acquisitions.
The added debt and the CVR obligations will weigh on the balance sheet until the loans are repaid or refinanced. The CVRs pay $2.00d per share if SYFOVRE annual net sales reach $1.5 billion in any of 2027–2030, and a further $2.00 per share if sales reach $2.0 billion in any of 2027–2031. The second milestone pays $4.00 instead if the first is missed by 2030 and the second is hit in 2031.
Each milestone pays only once, and there is no assurance either will be achieved. Investors should note that the filing refers to the deal's $4 maximum CVR value as conditional on SYFOVRE sales, which is a real risk given the product's current scale.
02—Key points
Key Highlights
- Tender offer expired May 13, 2026, with about 105.7 million Apellis shares (≈82.4%) validly tendered, satisfying the minimum condition; Apellis merged into a Biogen subsidiary May 14, 2026 under DGCL §251(h) with no stockholder vote.
- Consideration is $41.00 cash per share plus one non-transferable CVR; total cash purchase price is about $5.3 billion, excluding fees and CVR payments.
- CVR upside of up to $4.00 per share (about $582 million maximum aggregate) is tied to SYFOVRE annual net sales of $1.5 billion (2027–2030) and $2.0 billion (2027–2031).
- Acquired products EMPAVELI and SYFOVRE generated $689 million in combined 2025 net product revenue; Biogen expects the deal to be accretive to non-GAAP EPS in 2027.
- Financing: $2.0 billion unsecured term loans from U.S. Bank, fully drawn May 13, 2026, with $1.0 billion due May 2027 (364-day) and $1.0 billion due May 2028 (two-year).
- Credit agreement includes a maximum consolidated leverage covenant of 3.75x, temporarily increasable to 4.25x after material acquisitions, which constrains future capital flexibility.
- Updated financial guidance reflecting the acquisition is expected with Q2 2026 earnings in July 2026; the pro forma financial information will be filed by amendment later.
03—Questions
Frequently Asked Questions
What did Biogen pay to acquire Apellis, and what do shareholders receive?
Apellis shareholders received $41.00 in cash per share plus one non-transferable contingent value right (CVR) per share. The aggregate cash payment is approximately $5.3 billion, excluding fees and expenses and any CVR payments. Biogen estimates it would need about $582 million to pay the maximum CVR amounts if all milestones are achieved.
What must happen for CVR holders to receive payment?
Each CVR pays $2.00 if SYFOVRE annual net sales reach at least $1.5 billion in any of 2027–2030. A second $2.00 payment requires annual net sales of at least $2.0 billion in any of 2027–2031. If the first milestone is missed by December 31, 2030 but the second is achieved in 2031, the second milestone pays $4.00 instead. Each milestone pays only once, and there is no guarantee either will be met.
How is Biogen financing the acquisition, and what are the debt risks?
Biogen financed the deal with a $2.0 billion unsecured term loan facility from U.S. Bank, fully drawn on May 13, 2026. Tranche A ($1.0 billion) matures May 12, 2027, and Tranche B ($1.0 billion) matures May 12, 2028. Both bear floating rates of Term SOFR plus margins of 0.75% to 1.00%. The near-term maturity of Tranche A means Biogen will need to refinance or repay a substantial amount within about a year, and the leverage covenant of 3.75x (up to 4.25x temporarily) limits added borrowing.
Is the acquisition expected to be financially beneficial to Biogen?
Management expects the acquisition to be accretive to non-GAAP diluted EPS in 2027 and to materially increase Biogen's non-GAAP EPS compound annual growth rate through the end of the decade. Apellis's EMPAVELI and SYFOVRE generated $689 million in combined net product revenue in 2025. Updated guidance will be provided with Q2 2026 earnings in July. Investors should note that these projections are forward-looking and subject to integration and product-sales risks.
What are the main risks to the acquisition's value?
Key risks include the possibility that the CVR sales thresholds are never met, integration difficulties in realizing expected benefits, competition from new therapies, biosimilars and generics, pricing and reimbursement pressure, and the safety profile of the products. The filing notes SYFOVRE carries warnings for endophthalmitis, retinal detachment, retinal vasculitis, and neovascular AMD, while EMPAVELI carries a boxed warning for serious encapsulated-bacteria infections. Biogen also faces higher leverage from the new debt.
04—Continue